A committee of clinical trial monitors has advised Pliant Therapeutics to stop giving its experimental fibrosis drug to patients in a Phase 2 trial, seeding doubt about the therapy’s future.

Pliant disclosed few details and said it is ... This IPF drug candidate was discovered with Insilico’s artificial intelligence platform technology.

Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a ...

Pliant Therapeutics, Inc. (PLRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Pliant Therapeutics (NASDAQ:PLRX) stock plunged 61% in the wake of news that it has paused enrollment in a Phase 2b study of its drug bexotegrast in patients with idiopathic pulmonary fibrosis.

Pliant Therapeutics has pumped the breaks on a midstage trial of its lead lung disease drug on the advice of its safety committee. The South San Francisco biotech has been evaluating 160-mg and ...

Pliant Therapeutics paused enrollment in its BEACON-IPF Phase 2b trial of bexotegrast after a safety board review. Get access to your new suite of high-powered trading tools, including real-time ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report). The company’s shares closed last Friday at $7.79. Leverage the ...